JPMorgan Chase & Co. Has $16.86 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

JPMorgan Chase & Co. lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 60.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 720,798 shares of the biopharmaceutical company’s stock after acquiring an additional 270,286 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.46% of TG Therapeutics worth $16,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TGTX. NBC Securities Inc. grew its stake in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the period. Quarry LP grew its position in shares of TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 503 shares during the period. Private Advisor Group LLC increased its stake in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 542 shares in the last quarter. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares during the period. Finally, KBC Group NV boosted its stake in TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,092 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $28.88 on Friday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The business’s 50-day moving average price is $31.45 and its two-hundred day moving average price is $25.28. The stock has a market cap of $4.50 billion, a P/E ratio of -288.77 and a beta of 2.24. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.73 earnings per share. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TGTX shares. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright raised their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,358 shares of company stock valued at $781,497 in the last quarter. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.